Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. The company also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1988 and is headquartered in Queensbury, New York.
Frequently asked questions
What sector does Delcath Systems Inc (DCTH) operate in?
Delcath Systems Inc belongs to the Healthcare sector and operates in the Medical Devices industry.
What is Delcath Systems Inc (DCTH) current stock price?
As of the latest data, Delcath Systems Inc stock price is $16.86, with a previous close of $17.05. Delcath Systems Inc lost -$0.19 in the last trading session, representing a -1.11% loss.
What is Delcath Systems Inc (DCTH) current market capitalization?
Delcath Systems Inc market cap is approximately 585.02 million.
What is Delcath Systems Inc (DCTH) Earnings Per Share (EPS)?
The trailing EPS is $0.01, and the forward EPS is $0.08.
What is Delcath Systems Inc (DCTH) Price-to-Earnings (P/E) ratio?
Delcath Systems Inc current P/E ratio is 1,686, with a forward P/E of 224.8.
What is Delcath Systems Inc (DCTH) EBITDA?
Delcath Systems Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 3.26 million.
Does Delcath Systems Inc (DCTH) pay dividends?
No. Delcath Systems Inc does not pay a dividend.
How did Delcath Systems Inc (DCTH) perform in its most recent earnings report?
In the last report (June 30, 2026), Delcath Systems Inc posted an EPS surprise of 143.75% and a revenue surprise of 6.06%.
What is Delcath Systems Inc (DCTH) beta (volatility) score?
Delcath Systems Inc has a beta of 0.523, indicating lower volatility than the overall market.
